¿Qué es el Remdesivir? Luz verde en Europa al primer tratamiento contra la Covid-19

Se trata del primer fármaco que demuestra eficacia contra el coronavirus SARS-CoV-2

Coronavirus en España, en directo | Últimas noticias y rebrotes

Redacción

25/06/2020 17:19

La Agencia Europea del Medicamento (EMA) ha recomendado este jueves, por primera vez desde comienzos de la pandemia, autorizar la comercialización de un fármaco conocido como Veklury (Remdesivir) para el tratamiento de la Covid-19 en adultos y adolescentes de más de 12 años con neumonía.

Remdesivir es un antiviral que ralentiza la producción de nuevas partículas de virus y, como resultado, una infección viral se desarrolla con menos rapidez y los pacientes en estado grave se recuperan una media de cuatro días antes de lo habitual.

https://youtu.be/ecR34hYmvek

https://www.lavanguardia.com/vida/20200625/481948998404/que-es-el-remdesivir-primer-tratamiento-contra-coronavirus-covid-19-video-seo-lv.html

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

https://www.nature.com/articles/s41586-020-2423-5

This is an unedited manuscript that has been accepted for publication. Nature Research are providing this early version of the manuscript as a service to our authors and readers. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

• Brandi N. Williamson,
• Friederike Feldmann,
• Benjamin Schwarz,
• Kimberly Meade-White,
• Danielle P. Porter,
• Jonathan Schulz,
• Neeltje van Doremalen,
• Ian Leighton,
• Claude Kwe Yinda,
• Lizzette Pérez-Pérez,
• Atsushi Okumura,
• Jamie Lovaglio,
• Patrick W. Hanley,
• Greg Saturday,
• Catharine M. Bosio,
• Sarah Anzick,
• Kent Barbian,
• Tomas Cihlar,
• Craig Martens,
• Dana P. Scott,
• Vincent J. Munster &
• Emmie de Wit 

Nature (2020)Cite this article

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

https://www.nature.com/articles/s41586-020-2423-5

Abstract

Effective therapeutics to treat COVID-19 are urgently needed. While many investigational, approved, and repurposed drugs have been suggested, preclinical data from animal models can guide the search for effective treatments by ruling out treatments without in vivo efficacy. Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity^1,2, that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration^3,4. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection.^2,5,6 In vitro, remdesivir inhibited replication of SARS-CoV-2.^7,8 Here, we investigated the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection⁹. In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of respiratory disease and had reduced pulmonary infiltrates on radiographs and reduced virus titers in bronchoalveolar lavages 12hrs after the first treatment administration. Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment. At necropsy, lung viral loads of remdesivir-treated animals were lower and there was a reduction in damage to the lungs. Thus, therapeutic remdesivir treatment initiated early during infection had a clinical benefit in SARS-CoV-2-infected rhesus macaques. Although the rhesus macaque model does not represent the severe disease observed in a proportion of COVID-19 patients, our data support early remdesivir treatment initiation in COVID-19 patients to prevent progression to pneumonia.

Download PDF

Author information

Affiliations

1. Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA

   Brandi N. Williamson, Kimberly Meade-White, Jonathan Schulz, Neeltje van Doremalen, Claude Kwe Yinda, Lizzette Pérez-Pérez, Atsushi Okumura, Vincent J. Munster & Emmie de Wit

2. Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA

   Friederike Feldmann, Jamie Lovaglio, Patrick W. Hanley, Greg Saturday & Dana P. Scott

3. Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA

   Benjamin Schwarz, Ian Leighton & Catharine M. Bosio

4. Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA

   Sarah Anzick, Kent Barbian & Craig Martens

5. Gilead Sciences, Foster City, CA, USA

   Danielle P. Porter & Tomas Cihlar

Corresponding author

Correspondence to Emmie de Wit.

Supplementary information

Supplementary Table 1

Deep sequencing results to confirm absence of known resistance mutations to remdesivir.

Reporting Summary

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Williamson, B.N., Feldmann, F., Schwarz, B. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature (2020). https://doi.org/10.1038/s41586-020-2423-5

Download citation

• Received23 April 2020

• Accepted02 June 2020

• Published09 June 2020

• DOIhttps://doi.org/10.1038/s41586-020-2423-5

Share this article

Anyone you share the following link with will be able to read this content:

Provided by the Springer Nature SharedIt content-sharing initiative

Subjects

• Antivirals
• SARS-CoV-2
• Viral infection

Further reading

• Current Perspective of Antiviral Strategies against COVID-19

  • Bintou A. Ahidjo
  • , Marcus Wing Choy Loe
  • […]
  •  & Justin Jang Hann Chu

  ACS Infectious Diseases (2020)